James Hardie Industries $JHX claimed strong demand and normal inventory levels—but investors were blindsided when sales tanked and the stock dropped over 34 percent in just two days. In this episode of Sue Wall Street, we unpack the class action lawsuit alleging misleading statements, channel stuffing, and executive-level coverups. Perfect for retail investors, legal watchers, and finance sleuths. Get deep-dive analysis, sharp commentary, and red-flag warnings. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$BAX Baxter International is under fire after its “next-gen” infusion pump allegedly caused injuries, deaths and then a 22% stock plunge. In this episode of Sue Wall Street, we unpack the class action lawsuit claiming Baxter concealed life-threatening defects in its Novum IQ pump while touting its success to investors. If you're into medical tech, shareholder rights, or corporate cover-ups, tune in. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$MLTX MoonLake Immunotherapeutics lost nearly 90% of its stock value in one day after clinical trial results for its flagship nanobody drug disappointed investors. In this episode of Sue Wall Street, we dissect the class action lawsuit accusing MoonLake of hyping unproven biotech claims and misleading the market. If you follow biotech stocks, clinical trial risk, or Wall Street spin, don’t miss this one. Visit ZLK.com for more info. Add our WhatsApp Channel.We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$ATYR aTyr Pharma promised a steroid-free future with its experimental drug—but when their Phase 3 trial failed to meet its endpoint, the stock collapsed 83% in a single day. In this episode of Sue Wall Street, we unpack the class action lawsuit alleging investors were misled by overly optimistic claims. Biotech investors, clinical trial watchers, and Wall Street skeptics—this one's a must-listen. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$WPP told investors 2025 would be steady even “cautiously optimistic.” Then came the surprise: plummeting revenues, CEO retirement, and a trading update that sparked an 18% stock drop. In this episode of Sue Wall Street, we break down the securities class action accusing the global ad giant of misleading investors with overconfident projections. If you're into ad tech, investor risk, or corporate spin, this one's for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When $SVRA Savara Inc. filed its long-awaited FDA application, investors cheered—until the FDA refused to even review it. In this episode, we dive into the unfolding securities class action accusing Savara of misleading shareholders about its incomplete drug submission. Biotech investors, pharma followers, and Wall Street skeptics this one's for you. Expect sharp breakdowns, timely analysis, and a dose of biotech drama. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

A fresh class action lawsuit is shaking up $TROX Tronox Holdings, after investors claim the company misled them with glowing projections and shaky forecasting. In this episode of Sue Wall Street, we dive into how a drop in demand, a slashed dividend, and a brutal 38% stock plunge triggered legal action. If you're an investor, trader, or just love corporate drama, tune in for sharp insights, expert analysis, and sarcastic pigment puns. Visit ZLK.com for more info. Add our WhatsApp Channel.We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Did $CYTK gamble with the FDA and lose investor trust? In this episode of Sue Wall Street, we unpack the class action lawsuit against Cytokinetics Inc. Despite strong Phase 3 results, the company skipped a critical REMS in their NDA, delaying drug approval and tanking their stock. If you're into biotech moves, FDA filings, or securities law drama, this deep dive is for you. Learn how one missing document may cost shareholders millions. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Was $VFC walking investors into a turnaround—or a trap? In this episode of Sue Wall Street, we dive into the class action lawsuit against V.F. Corporation, the company behind Vans, The North Face, and Timberland. While hyping its “Reinvent” strategy, VFC allegedly hid plans for a second major reset—until surprise earnings revealed a 20% Vans revenue drop. If you follow retail stocks, brand comebacks, or securities litigation, this one's for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Was $FLR engineering confidence or just misleading investors? In this episode of Sue Wall Street, we dive into the securities class action lawsuit against Fluor Corporation. If you're tracking construction giants, infrastructure deals, or suspiciously sunny earnings calls, this one’s for you. We unpack how project delays, cost overruns, and executive stock sales all led to a brutal 27% drop in one day—and a whole lot of legal fallout. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

What happens when a biotech company tells investors one thing and delivers another? In this episode of Sue Wall Street, we unpack the securities class action against Savara Inc. $SVRA’s inhaled drug for rare lung disease was supposed to be a breakthrough—until the FDA refused to even review their application. If you're a biotech investor, compliance nerd, or just love a good Wall Street unraveling, this deep dive is for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Was $LNTH hiding the truth? In this episode of Sue Wall Street, Cassie and Bill unpack the shocking securities class action lawsuit against Lantheus Holdings. Biotech investors, this one’s for you: we dig into Pylarify’s pricing fallout, executive silence, and a stock freefall that left shareholders stunned. Expect sharp analysis, legal breakdowns, and just enough outrage to fuel your next portfolio check. Whether you’re into earnings calls, SEC filings, or drama on the NASDAQ, tune in. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Tesla’s $TSLA Robotaxi dreams hit a legal speed bump. In this episode of Sue Wall Street, we dive deep into the securities class action targeting Tesla and Elon Musk. Shareholders allege misleading claims about autonomous driving tech, safety, and AI, all while the stock took a sharp turn. Perfect for investors, financial sleuths, and courtroom junkies. Expect insider details, analysis, and sharp banter. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Novo Nordisk $NVO promised blockbuster weight loss from its new drug CagriSema—touting 25% results. But when final trial data landed at 22.7%, investors were stunned. In this episode of Bulls & Betrayal, Anna and Nate dig into the class action lawsuit accusing Novo of misleading shareholders about trial design and results. Perfect for biotech investors, legal watchers, and pharma skeptics, this episode exposes the risks behind drug hype. Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Lockheed Martin $LMT is facing a massive class action after revealing nearly $5 billion in losses tied to secretive government contracts. In this episode of Sue Wall Street, Cassie and Bill unravel how one of the largest defense contractors allegedly misled investors while quietly hemorrhaging money. Perfect for retail investors, financial sleuths, and anyone watching corporate accountability, this deep dive blends drama, SEC filings, and shareholder lawsuits. Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When Sable Offshore $SOC announced its oil production had resumed, investors rushed in—and the stock jumped 14%. But the truth? No real restart, just well testing. In this episode of Sue Wall Street, Cassie and Bill uncover how one press release, one $295M secondary offering, and one harsh reality check triggered a class action lawsuit. Perfect for investors, analysts, and compliance pros, this episode blends sharp commentary with deep legal insight.   Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$LINE’s blockbuster IPO raised billions—but did it freeze out the truth? In this episode of Sue Wall Street, we unpack the class action lawsuit alleging Lineage misled investors about plunging demand, evaporating inventory, and a deep freeze in fundamentals. With private equity payouts, post-COVID market distortions, and a fired auditor, this case is a must-listen for IPO investors, pension funds, and anyone tracking Wall Street accountability. Expect deep dives, sharp takes, and frosty truths. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When $FLYW’s stock plunged 37% in a single day, investors were blindsided. In this episode of Sue Wall Street, we break down the new class action lawsuit accusing Flywire of downplaying massive headwinds from international student visa caps while hyping their growth narrative. If you're into SaaS stocks, fintech drama, or shareholder rights, this one's for you. Expect insider breakdowns, sharp commentary, and red flags you don’t want to miss. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Was $FI’s explosive growth just a billing trick? In this episode of Sue Wall Street, we unpack the class action lawsuit alleging that Fiserv misled investors by calling forced migrations to its Clover platform "organic growth." Small businesses pushed off the Payeezy system didn’t stick around—and when they fled, the stock followed. If you're a fintech investor, shareholder advocate, or SEC rules junkie, this one's for you. Expect exposés, sharp analysis, and unraveling KPIs. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When $DOW slashed its dividend by 50% after months of rosy forecasts, investors were left reeling—and a securities fraud lawsuit quickly followed. In this episode of Sue Wall Street, we unpack the allegations that Dow Inc. misled shareholders about financial stability, masking demand drops and oversupply issues in key markets. Perfect for retail investors, dividend chasers, and finance nerds who love a good Wall Street reckoning. Expect sharp commentary, deep dives, and corporate accountability. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.